A preliminary study of imiquimod treatment in variants of basal cell carcinoma

American Surgeon

Volumn 71, Issue 8, 2005, Pages 662-665

  McCutcheon, Brion ^a   White, Kenneth ^a   Kotwall, Cyrus ^a   Germolic, Dori ^b   Rebolloso, Yvette ^b   Hamann, Mary Sue ^a   Stiles, Anquonette ^a  

^a New Hanover Regional Medical Center   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; AMINOQUINOLINE DERIVATIVE; IMMUNOLOGICAL ADJUVANT;

ADULT; ARTICLE; BASAL CELL CARCINOMA; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; TUMOR BIOPSY; BIOPSY; PATHOLOGY; PILOT STUDY; SKIN; SKIN TUMOR; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; AMINOQUINOLINES; BIOPSY; CARCINOMA, BASAL CELL; HUMANS; PILOT PROJECTS; POLYMERASE CHAIN REACTION; SKIN; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 27744523399     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma; results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001;44:807-13.
2. Beutner KR, Gelsse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999;41:1002-7.
3. Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiqumod cream for the treatment of nodular basal cell carcinoma. Arch Dermatol 2002;138:1165-71.
4. Wolf IH, Smolle J, Binder B, et al. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol 2003; 139:273-6.
5. Tyring SK, Arany I, Stanley MA, et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J Infect Dis 1998;178:551-5.
6. Arany I, Tyring SK, Stanley MA, et al. Enhancement of the innate and cellular immune response I patients with genital warts treated with topical imiquimod cream 5%. Antiviral Res 1999;43:55-63.
7. Saunder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2000;43:56-11.
8. Hengge UR, Benninghoff B, Ruzicka T, Goos M. Topical immunomodulators: progress towards treating inflammation, infection, and cancer. Lancet Infect Dis 2001;1:189-98.
9. Buechner SA, Wernli M, Harr T, et al. Regression of basal cell carcinoma hy intralesional interferon-alpha treatment in medicated by CD 95(Apo-1/Fas)-CD95 ligand-induced suicide. J Clin Invest 1997;100:2691-6.
10. Wehrli P, Viard I, Bullani R, et al. Death receptors in cutaneous biology and disease. J Invest Dermatol 2000;115:141-8.
11. Urosevic M, Maier T, Benninghoff B, et al. Mechanisms underlying imiquimod-induccd regression of basal cell carcinoma in vivo. Arch Dermatol 2003;139:1325-32.
12. Bath FJ, Bong J, Perkins W, Williams HC. Interventions for basal cell carcinoma of the skin. Cochrane Database of Systematic Reviews. (2)CD003412, 2003.
13. Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002;47:390-8.
14. Gutman M, Even-Sapir E, Merimsky O, et al. The role in interleukin-8 in the initiation and progression of human cutaneous melanoma. Anticancer Res 2002;22:3395-8.
15. Gutman M, Singh RK, Xie K, et al. Regulation of interleukin-8 expression in human melanoma cells by the organ environment. Cancer Res 1995;55:2470-5.
16. Ramjeesingh R, Leung R, Siu CH. Interleukin-8 secreted by endothelial cells induces chemotaxis of melanoma cells through the chemokine receptor CXCR1. FASEB J 2003;17:1292-4.